No, Dr. Daud's assessment regarding clinically meaningful responses in this patient population appears to be spot on. Success has a benchmark, and it is below 20%. Both Oncosec and DVAX are leading this race toward rescuing refractory anti-pd-1 patients. This is not an all comers or treatment naive patient population. It is a subset of advanced melanoma patients who have essentially no options remaining after failure on pembro or nivo.
Based on prior observations, the reported PISCES patients will more than likely see deepening responses over time. Just my opinion.
News 
Market Data 
Discover 
